Literature DB >> 36027915

Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance.

Ningbo Zheng1, Jing Fang1, Gang Xue1, Ziyu Wang1, Xiaoyin Li2, Mengshi Zhou2, Guangxu Jin1, Masmudur M Rahman3, Grant McFadden4, Yong Lu5.   

Abstract

Cytotoxicity of tumor-specific T cells requires tumor cell-to-T cell contact-dependent induction of classic tumor cell apoptosis and pyroptosis. However, this may not trigger sufficient primary responses of solid tumors to adoptive cell therapy or prevent tumor antigen escape-mediated acquired resistance. Here we test myxoma virus (MYXV)-infected tumor-specific T (TMYXV) cells expressing chimeric antigen receptor (CAR) or T cell receptor (TCR), which systemically deliver MYXV into solid tumors to overcome primary resistance. In addition to T cell-induced apoptosis and pyroptosis, tumor eradication by CAR/TCR-TMYXV cells is also attributed to tumor cell autosis induction, a special type of cell death. Mechanistically, T cell-derived interferon γ (IFNγ)-protein kinase B (AKT) signaling synergizes with MYXV-induced M-T5-SKP-1-VPS34 signaling to trigger robust tumor cell autosis. CAR/TCR-TMYXV-elicited autosis functions as a type of potent bystander killing to restrain antigen escape. We uncover an unexpected synergy between T cells and MYXV to bolster solid tumor cell autosis that reinforces tumor clearance.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CAR-T cells; acquired resistance; autosis; myxoma virus

Mesh:

Substances:

Year:  2022        PMID: 36027915      PMCID: PMC9489043          DOI: 10.1016/j.ccell.2022.08.001

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   38.585


  47 in total

1.  Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule.

Authors:  N Holler; R Zaru; O Micheau; M Thome; A Attinger; S Valitutti; J L Bodmer; P Schneider; B Seed; J Tschopp
Journal:  Nat Immunol       Date:  2000-12       Impact factor: 25.606

2.  CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.

Authors:  Josephine Walton; Julianna Blagih; Darren Ennis; Elaine Leung; Suzanne Dowson; Malcolm Farquharson; Laura A Tookman; Clare Orange; Dimitris Athineos; Susan Mason; David Stevenson; Karen Blyth; Douglas Strathdee; Frances R Balkwill; Karen Vousden; Michelle Lockley; Iain A McNeish
Journal:  Cancer Res       Date:  2016-08-16       Impact factor: 12.701

3.  Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas.

Authors:  Xueqing Lun; Wenqing Yang; Tommy Alain; Zhong-Qiao Shi; Huong Muzik; John W Barrett; Grant McFadden; John Bell; Mark G Hamilton; Donna L Senger; Peter A Forsyth
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

4.  Carrier cell-based delivery of an oncolytic virus circumvents antiviral immunity.

Authors:  Anthony T Power; Jiahu Wang; Theresa J Falls; Jennifer M Paterson; Kelley A Parato; Brian D Lichty; David F Stojdl; Peter A J Forsyth; Harry Atkins; John C Bell
Journal:  Mol Ther       Date:  2007-01       Impact factor: 11.454

5.  Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome.

Authors:  Yuying Liu; Yiliang Fang; Xinfeng Chen; Zhenfeng Wang; Xiaoyu Liang; Tianzhen Zhang; Mengyu Liu; Nannan Zhou; Jiadi Lv; Ke Tang; Jing Xie; Yunfeng Gao; Feiran Cheng; Yabo Zhou; Zhen Zhang; Yu Hu; Xiaohui Zhang; Quanli Gao; Yi Zhang; Bo Huang
Journal:  Sci Immunol       Date:  2020-01-17

6.  FBXL20-mediated Vps34 ubiquitination as a p53 controlled checkpoint in regulating autophagy and receptor degradation.

Authors:  Juan Xiao; Tao Zhang; Daichao Xu; Huibing Wang; Yu Cai; Taijie Jin; Min Liu; Mingzhi Jin; Kejia Wu; Junying Yuan
Journal:  Genes Dev       Date:  2015-01-15       Impact factor: 11.361

Review 7.  The molecular machinery of regulated cell death.

Authors:  Daolin Tang; Rui Kang; Tom Vanden Berghe; Peter Vandenabeele; Guido Kroemer
Journal:  Cell Res       Date:  2019-04-04       Impact factor: 25.617

8.  Single-cell imaging of CAR T cell activity in vivo reveals extensive functional and anatomical heterogeneity.

Authors:  Marine Cazaux; Capucine L Grandjean; Fabrice Lemaître; Zacarias Garcia; Richard J Beck; Idan Milo; Jérémy Postat; Joost B Beltman; Eleanor J Cheadle; Philippe Bousso
Journal:  J Exp Med       Date:  2019-04-01       Impact factor: 14.307

Review 9.  Prospects for combined use of oncolytic viruses and CAR T-cells.

Authors:  Adam Ajina; John Maher
Journal:  J Immunother Cancer       Date:  2017-11-21       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.